The utility of Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA) in Programmed Death Ligand-1 (PDL-1) analysis of Non-Small Cell Lung Cancer (NSCLC)

Introduction: The EBUS-TBNA is a minimally invasive technique widely used in the diagnosis, staging and immunohistochemistry analysis of lung cancer.1PDL-1 is a checkpoint on NSCLC that can be targeted with immunotherapy.2Routine PDL-1 testing was introduced at Oxford University Hospital NHS Foundation Trust (OUHFT) in 2017 and it is unclear if EBUS-TBNA provides adequate tissue for testing. In our current practice at the OUHFT, all NSCLC cases (Squamous Cell Lung Carcinoma and Lung Adenocarcinoma) identified on cytopathology are subsequently tested for PDL-1 tumour percentage score (TPS). The aim of this study was to see whether or not EBUS-TBNA samples provide adequate tissue for PDL-1 testing.Material and Methods: We retrospectively reviewed PDL-1 results of all NSCLC patients diagnosed by EBUS-TBNA during the year 2018 at OUHFT.Results: A total of 27 cases were diagnosed to have NSCLC on EBUS-TBNA samples in 2018. Out of 27,a total of 22 cases were tested for PDL-1. Of the 5 not tested,4 were not suitable for treatment and 1 had alternative sampling prior to EBUS.Of 22 tested cases, 17(77.2%) had adequate EBUS-TBNA sample for PDL-1 testing. 5(22.8%) were non-diagnostic due to insufficient sample.The TPS was negative(
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research

Related Links:

This study explores the diagnostic significance of microfluidic chip technology in the detection of CTCs/CSCs in clinical staging and metastasis of patients with non-small cell lung cancer (NSCLC). That lays a solid foundation for the use of microfluidic chips to monitor CTCs/CSCs for the stage and metastasis of patients with non-small cell lung cancer. PATIENTS AND METHODS: This study collected 80 patients with lung cancer from October 2017 to October 2018. Meanwhile, 30 healthy people and 30 patients with benign lung diseases were selected during the same period as the control group 1 and the control group 2, respect...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
In this study, we aimed to compare protocol compliance and toxic complications during adjuvant chemotherapy after intubated and nonintubated VATS lobectomies in non‐small cell lung cancer (NSCLC).MethodsWe retrospectively reviewed the medical records of 66, stage IB –IIIB NSCLC patients who underwent intubated or nonintubated VATS lobectomy and received adjuvant chemotherapy.ResultsA total of 38 patients (17 males, mean age 64  years) underwent conventional VATS and 28 (7 males; mean age 63 years) uniportal VATS NITS. Both groups had comparable demographic data, preoperative pulmonary function, and Ea...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conclusions: miR-25-3p may be a potential prognostic biomarker in non-small cell lung cancer. Genes targeted by miRNAs regulate EGFR and TGFβ signaling, among other known pathways relevant to lung tumorigenesis.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionsThese findings elucidate that YTHDC2 suppresses tumorigenesis in NSCLC, indicating that YTHDC2 may be a promising therapeutic target for NSCLC.Key pointsSignificant findings of the studyThis study demonstrated that the downregulation of YTHDC2 promotes tumor progression and predicts poor prognosis in non ‐small cell lung cancer (NSCLC).What this study addsYTHDC2 might be a promising therapeutic target for non ‐small cell lung cancer (NSCLC).
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
In this study, we analyzed the largest NSCLC cohort by mass spectrometry imaging (MSI) to date. We sought to test different classification algorithms and to validate results obtained in smaller patient cohorts. Tissue microarrays (TMAs) from including adenocarcinoma (ADC, n = 499) and squamous cell carcinoma (SqCC, n = 440), were analyzed. Linear discriminant analysis, support vector machine, and random forest (RF) were applied using samples randomly assigned for training (66%) and validation (33%). The m/z species most relevant for the classification were identified by on-tissue tandem mass spectrometry and validated by i...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In conclusion, by carrying out a series of in-depth analyses, hub genes and key pathways associated with early NSCLC were identified by a global transcriptional regulatory landscape. PMID: 32931455 [PubMed - as supplied by publisher]
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
Authors: Kim BS, Kang J, Jun S, Kim H, Pak K, Kim GH, Heo BJ, Kim YH Abstract OBJECTIVE: To assess associations between parameters derived from F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and mRNA expression levels of immune checkpoint biomarkers such as programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4) as well as tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Integrated data were downloaded from Genomic Data Common Data Portal. Clinical, mRNA-seq, and whole exome-seq data of lu...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
AbstractAlthough genome-wide association studies have identified more than eighty genetic variants associated with non-small cell lung cancer (NSCLC) risk, biological mechanisms of these variants remain largely unknown. By integrating a large-scale genotype data of 15 581 lung adenocarcinoma (AD) cases, 8350 squamous cell carcinoma (SqCC) cases, and 27 355 controls, as well as multiple transcriptome and epigenomic databases, we conducted histology-specific meta-analyses and functional annotations of both reported and novel susceptibility variants. We identified 3064 credible risk variants for NSCLC, which were overrepresen...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
ConclusionSurgical-resected c-SCLCs have a relatively good prognosis. TNM stage is the most significant factor influencing disease progression in surgical-resected c-SCLCs. SUVmax and mixed NSCLC components within c-SCLCs had a considerable influence on the survival. Both high SUVmax and mixed SCC component are poor predictors for patients with c-SCLCs.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsTP53 mutations are potentially markers of poor prognosis for stage I lung adenocarcinoma patients. The mutation status of this gene may contribute to clinical decision ‐making with respect to selecting patients who may benefit from adjuvant therapy.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Adenocarcinoma | Bronchoscopy | Cancer | Cancer & Oncology | Carcinoma | Fine Needle Aspiration | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Oxford University | Respiratory Medicine | Squamous Cell Carcinoma | Study | Ultrasound